Please use this identifier to cite or link to this item: https://hdl.handle.net/10356/163126
Title: Structural and mechanistic insights into Mycobacterium abscessus as-partate decarboxylase PanD and a pyrazinoic acid-derived inhibitor
Authors: Saw, Wuan Geok
Leow, Chen Yen
Harikishore, Amaravadhi
Shin, Joon
Cole, Malcolm S.
Aragaw, Wassihun Wedajo
Ragunathan, Priya
Hegde, Pooja
Aldrich, Courtney C.
Dick, Thomas
Grüber, Gerhard
Keywords: Science::Biological sciences::Biochemistry
Science::Biological sciences::Biophysics
Issue Date: 2022
Source: Saw, W. G., Leow, C. Y., Harikishore, A., Shin, J., Cole, M. S., Aragaw, W. W., Ragunathan, P., Hegde, P., Aldrich, C. C., Dick, T. & Grüber, G. (2022). Structural and mechanistic insights into Mycobacterium abscessus as-partate decarboxylase PanD and a pyrazinoic acid-derived inhibitor. ACS Infectious Disease, 8(7), 1324-1335. https://dx.doi.org/10.1021/acsinfecdis.2c00133
Project: NRF-CRP18-2017- 01
RG107/20
Journal: ACS Infectious Disease
Abstract: Mycobacterium tuberculosis (Mtb) aspartate decarboxylase PanD is required for biosynthesis of the essential cofactor coenzyme A and targeted by the first line drug pyrazinamide (PZA). PZA is a prodrug that is converted by a bacterial amidase into its bioactive form pyrazinoic acid (POA). Employing structure-function analyses we previously identified POA-based inhibitors of Mtb PanD showing much improved inhibitory activity against the enzyme. Here, we performed the first structure-function studies on PanD encoded by the non-tuberculous mycobacterial lung pathogen Mycobacterium abscessus (Mab), shedding light on the differences and similarities of Mab and Mtb PanD. Solution X-ray scattering data provided the solution structure of the entire tetrameric Mab PanD, which in comparison to the structure of the derived C-terminal trun-cated Mab PanD1-114 mutant, revealed the orientation of the four flexible C-termini relative to the catalytic core. Enzymatic studies of Mab PanD1-114 explored the essentiality of the C-terminus for catalysis. A library of recombinant Mab PanD mutants based on structural information and PZA/POA resistant PanD mutations in Mtb, illuminated critical residues involved in the substrate tunnel and enzymatic activity. Using our library of POA analogs, we identified (3-(1-naphthamido)pyrazine-2-car-boxylic acid) (analog 2) as the first potent inhibitor of Mab PanD. The inhibitor shows mainly electrostatic- and hydrogen bonding interaction with the target enzyme as explored by isothermal titration calorimetry and confirmed by docking studies. The observed unfavorable entropy indicates that significant conformational changes are involved in the binding process of analog 2 to Mab PanD. In contrast to PZA and POA, which are whole-cell inactive, analog 2 exerts appreciable antibacterial activity against the three subspecies of Mab.
URI: https://hdl.handle.net/10356/163126
ISSN: 2373-8227
DOI: 10.1021/acsinfecdis.2c00133
Rights: This document is the Accepted Manuscript version of a Published Work that appeared in final form in ACS Infectious Diseases, copyright © 2022 American Chemical Society, after peer review and technical editing by the publisher. To access the final edited and published work see https://doi.org/10.1021/acsinfecdis.2c00133.
Fulltext Permission: embargo_20230715
Fulltext Availability: With Fulltext
Appears in Collections:SBS Journal Articles

Files in This Item:
File Description SizeFormat 
revised_manuscript_Saw_et_al_010622.pdf
  Until 2023-07-15
1.49 MBAdobe PDFUnder embargo until Jul 15, 2023

SCOPUSTM   
Citations 50

2
Updated on Nov 27, 2022

Web of ScienceTM
Citations 50

1
Updated on Dec 1, 2022

Page view(s)

9
Updated on Dec 4, 2022

Google ScholarTM

Check

Altmetric


Plumx

Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.